Oneness Biotech Co (LUX:ONEA) LT-Debt-to-Total-Asset : 0.03 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Oneness Biotech Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Oneness Biotech Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.03.

Oneness Biotech Co's long-term debt to total assets ratio increased from Dec. 2022 (0.02) to Mar. 2024 (0.03). It may suggest that Oneness Biotech Co is progressively becoming more dependent on debt to grow their business.

Oneness Biotech Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Oneness Biotech Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oneness Biotech Co LT-Debt-to-Total-Asset Chart

Oneness Biotech Co Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.04

0.02

Oneness Biotech Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.02	0.02	0.02	0.02	0.03

Oneness Biotech Co LT-Debt-to-Total-Asset Calculation

Oneness Biotech Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )	/	Total Assets (A: Dec. 2022 )
	=	8.159	/	508.292
	=	0.02

Oneness Biotech Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	12.225	/	475.623
	=	0.03

Oneness Biotech Co (LUX:ONEA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Oneness Biotech Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Oneness Biotech Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Oneness Biotech Co (LUX:ONEA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oneness Biotech Co Ltd (LUX:ONEA) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

4743:Taiwan

Address

No. 236, Section 4, Xinyi Road, 11th Floor, Daan District, Taipei, TWN, 106

Website

https://www.onenessbio.com.tw

Oneness Biotech Co Ltd is a Taiwan based biopharmaceutical company. The company develops healthcare drugs. Its products are used for chronic diabetic, dengue hemorrhagic fever, and Rheumatoid Arthritis. The company's operating segment includes New Drug Research and Development and Agricultural Products Cultivation. It generates maximum revenue from New Drug Research and Development segment.

Oneness Biotech Co (LUX:ONEA) Headlines

No Headlines